SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-006965
Filing Date
2020-05-07
Accepted
2020-05-07 16:25:26
Documents
61
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20200331x10q1.htm   iXBRL 10-Q 1157513
2 EXHIBIT 10.1 ex101jamiedonadiosepar.htm EX-10.1 46530
3 EXHIBIT 10.2 ex102chrislemasterssep.htm EX-10.2 44624
4 EXHIBIT 31.1 mrtx03312020ex311.htm EX-31.1 12417
5 EXHIBIT 31.2 mrtx03312020ex312.htm EX-31.2 12878
6 EXHIBIT 32.1 mrtx03312020ex321.htm EX-32.1 8227
  Complete submission text file 0001628280-20-006965.txt   4630514

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20200331.xsd EX-101.SCH 32969
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20200331_cal.xml EX-101.CAL 49493
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20200331_def.xml EX-101.DEF 107928
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20200331_lab.xml EX-101.LAB 400024
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20200331_pre.xml EX-101.PRE 219118
35 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20200331x10q1_htm.xml XML 705056
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 20856854
SIC: 2834 Pharmaceutical Preparations